Trial reportJournal of child and adolescent psychopharmacology2014
Change in plasma cytokine levels during risperidone treatment in children with autism.
Trial report in Journal of child and adolescent psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Effects of Risperidone in Autistic Children and Young Adults: A Systematic Review and Meta-Analysis.Current neuropharmacology · 2021Pooled it
- Advancing understanding of the mechanisms of autism spectrum disorder through perinatal risk factors.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Altered Monocyte Populations and Activation Marker Expression in Children with Autism and Co-Occurring Gastrointestinal Symptoms.Biomolecules · 2025Article
- Microglial contribution to the pathology of neurodevelopmental disorders in humans.Acta neuropathologica · 2023Review
- Upregulation of Inflammatory Mediators in Peripheral Blood CD40International journal of molecular sciences · 2023Article
- Blood neurofilament light chain and thrombospondin-1 levels of patients with autism spectrum disorder.Turkish journal of medical sciences · 2022Article
- Immune Dysregulation in Autism Spectrum Disorder: What Do We Know about It?International journal of molecular sciences · 2022Review
- Autoimmune Encephalitis and Autism Spectrum Disorder.Frontiers in psychiatry · 2021Review
- Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics.Frontiers in endocrinology · 2020Review
- Elevated IL-16 expression is associated with development of immune dysfunction in children with autism.Psychopharmacology · 2019Article
- Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment?Molecular neurobiology · 2018Review
- Characterizing the Interplay Between Autism Spectrum Disorder and Comorbid Medical Conditions: An Integrative Review.Frontiers in psychiatry · 2018Review
- Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations.Journal of neuroinflammation · 2017Review
- The Immune System, Cytokines, and Biomarkers in Autism Spectrum Disorder.Neuroscience bulletin · 2017Review
- Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders.Molecular autism · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAtypical antipsychotics decrease irritability in autism. They also affect the cytokine network. Psychological stress, depression, and, possibly, autism spectrum disorder (ASD) are associated with the production of pro-inflammatory cytokines. We sought to determine if risperidone treatment led to changes in plasma cytokine levels.
methodsForty-five subjects from an open-label study of risperidone treatment of children and adolescents with ASD, ages 4-18 years, had an analysis of 27 different cytokines at baseline and after 8 weeks of treatment using multiplex assays (Millipore) and read on the Luminex 100(™) platform. We examined changes in each of the cytokine levels in the entire group, and also compared changes in cytokines in responders versus nonresponders.
resultsAfter 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (MCP-1) (p=0.0024). Six of the 48 subjects met two criteria for responders to risperidone, and the median values of interleukin (IL)-5 were significantly higher (p=0.005) in the overall responder group than in nonresponders.
conclusionsTwo cytokines, eotaxin and MCP-1, which have previously been identified as abnormally elevated in children with autism, decreased during treatment with risperidone. This suggests a possible mechanism of action of risperidone treatment and a balancing of the immune system in affected subjects in this very preliminary study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.